# US 2024/0158343 A1 · Isotope-enriched 3-amino-1-propanesulfonic acid derivatives and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0158343 A1
- Document ID: US20240158343A1
- Status: Published application
- Kind: A1
- Application number: 18/417,291
- Filed: 2024-01-19
- Published: 2024-05-16
- Earliest claimed: 2017-03-21
- Assignees: Risen (Suzhou) Pharma Tech Co., Ltd.
- Applicants: Risen (Suzhou) Pharma Tech Co., Ltd.
- Inventors: Jiasheng LU; Jiamin GU; Xinyong LV; Guowei SONG; Dongdong WU; Daiqiang HU; Jun GU; Gang CHEN; Xiang JI; Xiuchun ZHANG; Jinchao AI; Xianqi KONG
- Web page: https://patentgrep.com/patent/US20240158343A1

## CPC

- C07C 309/14: containing amino groups bound to the carbon skeleton
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07B 59/001: {Acyclic or carbocyclic compounds}
- C07B 59/002: {Heterocyclic compounds}
- C07C 309/15: the nitrogen atom of at least one of the amino groups being part of any of the groups [IMAGE cpc-sch-C07C-0975.gif], X being a hetero atom, Y being any atom
- C07C 309/59: Nitrogen analogues of carboxyl groups
- C07D 233/61: with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms
- C07B 2200/05: Isotopically modified compounds, e.g. labelled
- Y02P 20/55: Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- Y02P: CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS

## Abstract

There are provided isotope-enriched compounds of Formula (I) and pharmaceutically acceptable salts or esters thereof, as well as pharmaceutical compositions thereof and methods of use thereof for prevention and treatment of amyloid-β related diseases, such as Alzheimer's disease. R1R2X—CR2—CH2—CH2—SO3H (I)

## Claims

### Claim 1

A compound of Formula (I), or a pharmaceutically acceptable salt or ester thereof:
R1R2X—CR2—CH2—CH2—SO3H (I)
where:
R1 and R2 are independently a hydrogen of natural abundance or a protecting group, wherein said protecting group is isotope-enriched or non-isotope enriched, said protecting group being selected from acyl, carbonyl, thiocarbonyl, and carbamoyl groups;
X is a nitrogen of natural abundance or 15N, or a combination thereof; and
R is a hydrogen of natural abundance, a deuterium (D) or a combination thereof;
provided that at least one of X, R, R1 and R2 comprises an atom that is not of natural abundance.

### Claim 2 (depends on 1)

The compound of claim 1, wherein R is a hydrogen of natural abundance and X is 15N.

### Claim 3 (depends on 1)

The compound of claim 1, wherein R is D and X is a nitrogen of natural abundance.

### Claim 4 (depends on 1)

The compound of claim 1, wherein R is D and X is 15N.

### Claim 5 (depends on 1)

The compound of claim 1, wherein R is a hydrogen of natural abundance; X is a nitrogen of natural abundance; and at least one atom in R1 and/or R2 is not of natural abundance.

### Claim 6 (depends on 1)

The compound of claim 1, wherein the compound is a compound of Formula (II), or a pharmaceutically acceptable salt or ester thereof:
H2X—CR2—CH2—CH2—SO3H (II)
where:
X is a nitrogen of natural abundance, a 15N or a combination thereof; and
R is a hydrogen of natural abundance, a deuterium (D) or a combination thereof;
provided that R is not a hydrogen of natural abundance when X is a nitrogen of natural abundance.

### Claim 7 (depends on 6)

The compound of claim 6, wherein R is a hydrogen of natural abundance and X is 15N.

### Claim 8 (depends on 6)

The compound of claim 6, wherein R is D and X is a nitrogen of natural abundance.

### Claim 9 (depends on 6)

The compound of claim 6, wherein R is D and X is 15N.

### Claim 10 (depends on 1)

The compound of claim 1, wherein the compound is a compound of Formula (III), or a pharmaceutically acceptable salt or ester thereof:
where:
X is a nitrogen of natural abundance, a 15N or a combination thereof;
R is a hydrogen of natural abundance, a deuterium (D) or a combination thereof;
Y is a carbon of natural abundance, a 13C or a combination thereof;
Z is a sulfur of natural abundance, an oxygen of natural abundance, an 18O, an 17O or a combination thereof; and
R3 is a substituting group selected from substituted or unsubstituted alkyl, aryl, amino alkyl, amino arylalkyl, heterocyclyl, alkoxyl, alkylthio, alkylamino, acyloxyl, and thioacyloxyl;
provided that at least one of X, R, Y and Z is not an atom of natural abundance.

### Claim 11 (depends on 10)

The compound of claim 10, wherein R is not a hydrogen of natural abundance when X is a nitrogen of natural abundance.

### Claim 12 (depends on 10, 11)

The compound of claim 10 or 11, wherein R3, Y, and Z taken together form an acyl group connected to X, forming an amide bond linkage.

### Claim 13 (depends on 10, 11)

The compound of claim 10 or 11, wherein R3 is a natural or unnatural amino acid residue and R3, Y, and Z taken together form an acyl group connected to X, the acyl group being derived from a natural or unnatural amino acid.

### Claim 14 (depends on 13)

The compound of claim 13, wherein the natural or unnatural amino acid is an L-amino acid, a D-amino acid, or a mixture thereof.

### Claim 15 (depends on 13)

The compound of claim 13, wherein the natural or unnatural amino acid is a natural L-amino acid.

### Claim 16 (depends on 1)

The compound of claim 1, wherein the compound is a compound of Formula (IV), or a pharmaceutically acceptable salt or ester thereof:
where:
R4 is a side chain of a natural or unnatural amino acid;
O* is an oxygen atom of natural abundance, an 18O, an 17O or a combination thereof; and
C* is a carbon atom of natural abundance, a 13C or a combination thereof.

### Claim 17 (depends on 16)

The compound of claim 16, wherein the natural or unnatural amino acid is an L-amino acid, a D-amino acid, or a mixture thereof.

### Claim 18 (depends on 16)

The compound of claim 16, wherein the natural or unnatural amino acid is a natural L-amino acid.

### Claim 19 (depends on 1)

The compound of claim 1, wherein the compound is a compound of Formula (V), or a pharmaceutically acceptable salt or ester thereof:
where:
R4 is a side chain of a natural or unnatural amino acid;
O* is an oxygen atom of natural abundance, an 18O, an 17O or a combination thereof; and
C* is a carbon atom of natural abundance, a 13C or a combination thereof.

### Claim 20 (depends on 19)

The compound of claim 19, wherein the natural or unnatural amino acid is an L-amino acid, a D-amino acid, or a mixture thereof.

### Claim 21 (depends on 19)

The compound of claim 19, wherein the natural or unnatural amino acid is a natural L-amino acid.

### Claim 22 (depends on 1)

The compound of claim 1, wherein the compound is a compound of Formula (VI), or a pharmaceutically acceptable salt or ester thereof:
where:
R4 is a side chain of a natural or unnatural amino acid;
O# is an oxygen atom of natural abundance, an 18O, an 17O or a combination thereof;
C# is a carbon atom of natural abundance, a 13C or a combination thereof;
provided that at least one of O# and C# is an isotope-enriched atom.

### Claim 23 (depends on 22)

The compound of claim 22, wherein the natural or unnatural amino acid is an L-amino acid, a D-amino acid, or a mixture thereof.

### Claim 24 (depends on 22)

The compound of claim 22, wherein the natural or unnatural amino acid is a natural L-amino acid.

### Claim 25 (depends on 1)

The compound of claim 1, which is 3-amino-3,3-dideuterium-1-propanesulfonic acid or a pharmaceutically acceptable salt or ester thereof.

### Claim 26 (depends on 1)

The compound of claim 1, which is 3-(15N-amino)-1-propanesulfonic acid or a pharmaceutically acceptable salt or ester thereof.

### Claim 27 (depends on 1)

The compound of claim 1, which is
or a pharmaceutically acceptable salt or ester thereof.

### Claim 28 (depends on 1)

The compound of claim 1, which is
or a pharmaceutically acceptable salt or ester thereof.

### Claim 29 (depends on 1)

The compound of claim 1, which is
or a pharmaceutically acceptable salt or ester thereof.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The compound of any one of claims 1 to 29, wherein the level of isotope enrichment in the compound with isotopes that are not of natural abundance is about 2% or more, about 5% or more, about 10% or more, about 20% or more, about 50% or more, about 75% or more, about 90% or more, about 95% or more, or 100%.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

A pharmaceutical composition comprising the compound of any one of claims 1 to 30 and a pharmaceutically acceptable carrier.

### Claim 32 (depends on 31)

The pharmaceutical composition of claim 31, wherein the composition is suitable for oral administration.

### Claim 33 (depends on 31, 32)

The pharmaceutical composition of claim 31 or 32, wherein the composition is in the form of a hard shell gelatin capsule, a soft shell gelatin capsule, a cachet, a pill, a tablet, a lozenge, a powder, a granule, a pellet, a pastille, or a dragee.

### Claim 34 (depends on 31, 32)

The pharmaceutical composition of claim 31 or 32, wherein the composition is in the form of a solution, an aqueous liquid suspension, a non-aqueous liquid suspension, an oil-in-water liquid emulsion, a water-in-oil liquid emulsion, an elixir, or a syrup.

### Claim 35 (depends on 31, 32, 33, 34)

The pharmaceutical composition of any one of claims 31 to 34, wherein the composition is enteric coated.

### Claim 36 (depends on 31, 32, 33, 34, 35)

The pharmaceutical composition of any one of claims 31 to 35, wherein the composition is formulated for controlled release.

### Claim 37 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36)

A method for prevention or treatment of an amyloid-β related disease in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the compound of any one of claims 1 to 30 or the pharmaceutical composition of any one of claims 31 to 36, such that the amyloid-β related disease is prevented or treated in the subject.

### Claim 38 (depends on 37)

The method of claim 37, wherein the amyloid-β related disease is Alzheimer's disease, mild cognitive impairment (MCI), Down's syndrome, Hereditary Cerebral Hemorrhage with Amyloidosis of the Dutch-Type, cerebral amyloid angiopathy, a degenerative dementia, a dementia of mixed vascular and degenerative origin, dementia associated with Parkinson's disease, dementia associated with progressive supranuclear palsy, dementia associated with cortical basal degeneration, or dementia associated with diffuse Lewy body type of Alzheimer's disease.

### Claim 39 (depends on 37)

The method of claim 37, wherein the amyloid-β related disease is Alzheimer's disease, mild cognitive impairment, cerebral amyloid angiopathy, or degenerative dementia.

### Claim 40 (depends on 37)

The method of claim 37, wherein the amyloid-β related disease is Alzheimer's disease.

### Claim 41 (depends on 37, 38, 39, 40)

The method of any one of claims 37 to 40, wherein the subject is ApoE4 positive.
